The vaccine is formulated by combining peptides, proteins or carbohydrates of interest with a lipid anchor. This enables attachment to the surface of virosomes.
Employing this methodology creates a vaccine with high tolerability and safety, according to Pevion, which are particularly important traits when immunising against respiratory syncytial virus (RSV).
Having completed efficacy studies and proof-of-concept in the animal model, Pevion is aiming to begin clinical trials in 2011 or 2012.